{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:25:44Z","timestamp":1779103544843,"version":"3.51.4"},"reference-count":26,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Objective: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires advanced therapies, including infliximab, vedolizumab, and tofacitinib. Our aim is to understand the hospitalization rates and outcomes associated with these therapies in real-world scenarios, which is crucial for optimizing patient management and healthcare resource allocation.  Methods: This nationwide retrospective observational study analyzed real-world data (RWD) from Brazil\u2019s public healthcare system (SUS) between January 2021 and December 2023. Data on hospitalizations, length of stay, mortality, costs, and non-IBD-related hospital admissions were extracted and analyzed using the Techtrials TT Disease Explorer and TT RWE Generator, leveraging generative artificial intelligence (GenAI) for data integration and analysis.  Results: A total of 1,313 patients required hospitalization, with 1,434 hospitalizations recorded. The hospitalization rate per 100 patients was highest for tofacitinib (262.5), followed by infliximab (212.88) and vedolizumab (191.67). Patients treated with infliximab had the shortest hospital stay (Median 3.0 days [0-68]) and lowest costs (Median 510.83 BRL [23.45 - 111,594.14]), whilst vedolizumab had the highest hospitalization costs. Surgical intervention rates were highest among tofacitinib users. Non-IBD-related hospitalizations suggested potential adverse drug events, including gastrointestinal disorders, infections, and anemia.  Conclusion: This study represents the first AI-assisted RWE analysis of UC hospitalizations in Brazil. The findings highlight the varying hospitalization burdens across advanced therapies, with tofacitinib associated with higher hospitalization rates and infliximab linked to shorter hospital stays and lower costs. These insights can inform clinical decision-making and healthcare policy. Future studies should further explore AI\u2019s role in optimizing RWE research and UC management.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612025-066","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:52:01Z","timestamp":1779101521000},"source":"Crossref","is-referenced-by-count":0,"title":["GENERATIVE AI TOWARDS A COMPARATIVE ANALYSIS OF HOSPITALIZATION RATES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB, VEDOLIZUMAB, AND TOFACITINIB IN THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL: A NATIONWIDE STUDY"],"prefix":"10.1590","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5413-5486","authenticated-orcid":false,"given":"Douglas Andreas","family":"VALVERDE","sequence":"first","affiliation":[{"name":"Techtrials Pesquisa e Tecnologia LTDA,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-7402","authenticated-orcid":false,"given":"Abel Botelho","family":"QUARESMA","sequence":"additional","affiliation":[{"name":"Universidade do Oeste de Santa Catarina,  Brasil; Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0857-3520","authenticated-orcid":false,"given":"Maria Paz Gimenez","family":"VILLAMIL","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-3968","authenticated-orcid":false,"given":"Thyago Proen\u00e7a de","family":"MORAES","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-5315","authenticated-orcid":false,"given":"Paulo Gustavo","family":"KOTZE","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,  Brasil; Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi T","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The Role of Early Biologic Therapy in Inflammatory Bowel Disease","volume":"25","author":"Berg DR","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1756284819848631","DOI":"10.1177\/1756284819848631","article-title":"Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience","volume":"12","author":"D\u2019Amico F","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"ref4","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","author":"Vieujean S","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","series-title":"Relat\u00f3rio de Recomenda\u00e7\u00e3o do PCDT","year":"2022"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn\u2019s Disease in Population-Based Cohort Studies","volume":"67","author":"Tsai L","year":"2022","journal-title":"Dig Dis Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/ibd\/izad020","article-title":"Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study","volume":"29","author":"Buie MJ","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21). Global Hospitalization Trends for Crohn\u2019s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses","volume":"21","author":"Buie MJ","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1155\/2015\/627370","article-title":"Ulcerative colitis-associated hospitalization costs: a population-based study","volume":"29","author":"Coward S","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40258-018-0432-4","article-title":"Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States","volume":"17","author":"Xu F","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"ref11","series-title":"Banco de dados do Sistema \u00danico de Sa\u00fade- DATASUS","year":"2026"},{"key":"ref12","first-page":"100298","article-title":"Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study","volume":"3","author":"Quaresma AB","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"ref13","article-title":"Temporal Trends in Surgery and Hospitalization Rates for Crohn\u2019s Disease in Brazil: A Population-Based Study","author":"Reis Guerra JA","year":"2025","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.2196\/13659","article-title":"Artificial Intelligence and the Implementation Challenge","volume":"21","author":"Shaw J","year":"2019","journal-title":"J Med Internet Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3000605211000157","DOI":"10.1177\/03000605211000157","article-title":"Opportunities and challenges of artificial intelligence in the medical field: current application, emerging problems, and problem-solving strategies","volume":"49","author":"Jiang L","year":"2021","journal-title":"J Int Med Res"},{"key":"ref16","first-page":"0277","article-title":"SHIFTing artificial intelligence to be responsible in healthcare: A systematic review","volume":"114782","author":"Siala H","year":"2022","journal-title":"Social Science & Medicine"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1453194","DOI":"10.3389\/frobt.2024.1453194","article-title":"Advancements in the use of AI in the diagnosis and management of inflammatory bowel disease","volume":"11","author":"Braverman-Jaiven D","year":"2024","journal-title":"Front Robot AI"},{"key":"ref18","series-title":"Real-world evidence framework to support EU regulatory decision-making","year":"2024"},{"key":"ref19","series-title":"NICE real-world evidence framework"},{"key":"ref20","series-title":"A Revolu\u00e7\u00e3o da Gera\u00e7\u00e3o de Evid\u00eancias Cient\u00edficas com GenAI e RWE - TT Genius RWE Generator"},{"key":"ref21","article-title":"Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries","volume":"10","author":"Monteiro FSM","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review","volume":"17","author":"Steenholdt C","year":"2023","journal-title":"J Crohns Colitis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial","volume":"119","author":"Singh A","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"jjaf021","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","author":"Gisbert JP","year":"2025","journal-title":"J Crohns Colitis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S2468-1253(24)00229-2","article-title":"Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better","volume":"9","author":"Kedia S","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1177\/00031348241246160","article-title":"Safety and Efficacy of Inpatient Infliximab Rescue Therapy for Acute Crohn\u2019s Disease Flares","volume":"90","author":"Whitlock AE","year":"2024","journal-title":"Am Surg"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Intelig\u00eancia artificial generativa: uma an\u00e1lise comparativa das taxas de hospitaliza\u00e7\u00e3o entre pacientes com colite ulcerativa tratados com infliximabe, vedolizumabe e tofacitinibe no sistema p\u00fablico de sa\u00fade no Brasil"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032026000101802&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:52:05Z","timestamp":1779101525000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032026000101802&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"alternative-id":["S0004-28032026000101802"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612025-066","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e25066"}}